Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results
Gil Melmed, Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Laura E. Raffals(Mayo Clinic), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), William J. Sandborn(University of San Diego), Niels Vande Casteele(University of California San Diego), Leonard Baidoo(University of Pittsburgh Medical Center), Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Diane R. Mould(Phoenixville Hospital), Miles Sparrow(Alfred Health), Patricia Kozuch(Thomas Jefferson University), Jean-Fred Colombel(Icahn School of Medicine at Mount Sinai), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai)
Cited by 48
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k